An-Najah Staff

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in the treatment of different painful conditions. Their use is increasing due to the increased incidence of rheumatic diseases. Although generally well tolerated, these drugs are associated with serious adverse reactions such as upper gastrointestinal ulcers and bleeding, hypersensitivity reactions and renal failure. NSAIDs use can improve the quality of life for patients, but may also result in adverse health outcomes if used inappropriately. NSAIDs prescription-related problems (NSAIDs PRPs) can cause considerable morbidity and mortality, and may lead to hospital admission. Purpose: The objectives of this study are (1) to obtain information regarding the prevalence of NSAIDs PRPs and (2) to determine the demographic and clinical characteristic of patients exposed to these problems. Methods: We retrospectively collected data from one academic year using computerised databases at the Universiti Sains Malaysia (USM) from patients of USM’s primary care. Lists of NSAIDs PRPs were developed from authentic clinical pharmacy and drug information sources. Multivariate regression was used to determine the characteristics of patients exposed to NSAIDs PRPs. Results: During the study period, 12,622 of NSAID items were Prescribed for 6,518 patients (mean ± SD = 1.94 ± 1.90). This represented a prevalence of 36 %. Five hundred and ninety one NSAIDs PRPs were identified in a cohort of 434 patients, representing an exposure prevalence of 6.7 % of all NSAID users. Multivariate logistic regression analysis revealed that patients being Malay, being a staff, having multiple prescriptions and having more comorbid conditions were more likely to be exposed to NSAIDs PRPs. Conclusions: This is the first study in Malaysia that presents data on the prevalence of NSAIDs PRPs. Exposure to these problems is associated with specific socio-demographic and health status factors. These results should help to raise the awareness of clinicians about serious NSAIDs PRPs.